DLBCL

During a live virtual event, Beth A. Christian, MD, discussed data on third-line loncastuximab tesirine treatment in patients with diffuse large B-cell lymphoma and how to sequence treatments for patients who may receive CAR T-cell therapy.

Following 6 well-tolerated cycles of R-CHOP, a 75-year-old patient with diffuse large B-cell lymphoma showed complete remission on a PET scan. But 1 year later, the disease relapsed.

During a live virtual event, Beth A. Christian, MD, discussed real-world challenges of providing timely access to CAR-T cell therapy for patients with diffuse large B-cell lymphoma.

During a live virtual event, Beth A. Christian, MD, discussed approaches to third-line treatment of transplant-ineligible DLBCL and when to consider CAR T-cell therapy.

Jason Westin, MD, discusses unmet clinical needs in diffuse large B-cell lymphoma landscape. 

While antibody-drug conjugates have shown promise in patients with relapsed/refractory diffuse large B-cell lymphoma, there are other options that can help patients before moving on to CAR T-cell therapy.

Eleven months after completing therapy for diffuse large B-cell lymphoma, a 43-year-old patients reported fever, night sweats, and back pain, and a palpable lymph node was discovered in her left groin.

Justin Kline, MD, discusses what makes loncastuximab tesirine-lpyl a good bridge therapy for patients with relapsed/refractory diffuse large B-cell lymphoma to potential CAR T-cell therapy.

One year after a 75-year-old patient with diffuse large B-cell lymphoma achieved remission following 6 cycles of R-CHOP, the patient relapsed but declined transplant.

Looking at the challenges with CAR T-cell therapies in patients with diffuse large B-cell lymphoma Justin Kline, MD, discusses the best available therapies for patients who relapse on treatment.

The agent, EZM0414, will be explored in DLBCL, multiple myeloma, and non-multiple myeloma after the completion of a phase 1 dose-finding study.

The efficacy and data for the combination of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma show effective outcomes for patients that clinicians can use when discussing treatment options.

Eleven months after completion of therapy with the R-CHOP regimen, a 43-year-old patient with diffuse large B-cell lymphoma presented with fever, drenching night sweats, and recurrent back pain.

Looking at the combination of lenalidomide plus tafasitamab for patients with diffuse large B-cell lymphoma shows promise for patients' treatment, but challenges remain that clinicians need to address.

Jason Westin, MD, discusses the future of diffuse large B-cell lymphoma treatment.

During a live virtual event with other physicians, Bijal Shah, MD, MS, discussed treatment options for patients with diffuse large B-cell lymphoma and the data that backs up the efficacy for these options.

75-year-old man presented with fever, a 7-lb unintentional weight loss, and occasional chest pain.

In an interview with Targeted Oncology, Jason Westin, MD, discussed the future of DLBCL treatment in both the frontline and later-line settings, along with current unmet clinical needs.

Eleven months after completion of therapy with the R-CHOP regimen, a 43-year-old woman with diffuse large B-cell lymphoma complained of fever, night sweats, and back pain.

Jason Westin, MD, discusses the current standard of care in diffuse large B-cell lymphoma.

In an interview with Targeted Oncology, Brad S. Kahl, MD, provided an efficacy update from the LOTUS-2 study and discussed multiple agents showing promise for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Encouraging results have been reported from the phase 2 Guidance-01 clinical trial.

Mehdi Hamadani, MD and Bertram Glass, MD recently debated on the role of allogeneic hematopoietic stem cell transplant for the treatment of aggressive B-cell lymphoma now that chimeric antigen receptor T cells have entered the landscape.

During a Targeted Oncology Case-Based Roundtable event, John M. Burke, MD, discussed the challenges with treating relapsed or refractory diffuse large B-cell lymphoma with a group of peers.

Expert insight on the GO29365 trial, which informs selection of polatuzumab + bendamustine and rituximab in patients with relapsed/refractory DLBCL.

Daniel O. Persky, MD, reflects on a patient’s relapse with diffuse large B-cell lymphoma and the rationale behind treatment with polatuzumab + BR.

A review of frontline treatment options for DLBCL informed by comprehensive patient workup and the efficacy of available therapies.

Expert hematologist/oncologist Daniel O. Persky, MD, reviews the case of a 73-year-old woman who is diagnosed with and treated for DLBCL, later to relapse and require novel therapy.

Christopher R. Flowers, MD, discusses the current therapies used for patients with relapsed/refractory diffuse large B-cell lymphoma and goes into specifics of the L-MIND trial after the long-term follow-up.

Grzegorz S. Nowakowski, MD and Stephen D. Smith lead other participants of a Case Based Roundtable event in a discussion around treatment for patients with transplant-ineligible diffuse large B-cell lymphoma.